| Literature DB >> 29439058 |
Kushan Karunaratne1, Dimitri Amiras2, Matthew C Pickering3, Monika Hofer4, Stuart Viegas1.
Abstract
Statins lower serum cholesterol concentrations by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). Muscle side effects are relatively common and include asymptomatic elevation of serum creatine kinase (CK), myalgia, proximal muscle weakness and rhabdomyolysis. More recently, a subset of cases of immune-mediated necrotising myopathy has been found to have antibodies against HMGCR. It is often an aggressive and debilitating myopathy and has a complex pathogenesis characterised by fibre necrosis, usually with minimal associated inflammation. Not all such patients are taking statins. The general consensus is that best treatment involves withdrawing the statin and giving immunosuppressive and immunomodulatory treatment. We describe three cases of HMGCR-related immune-mediated necrotising myopathy, detailing their clinical course and subsequent management, illustrating the spectrum of this disorder. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Entities:
Keywords: HMG-CoA reductase; autoantibodies; myopathy; necrotizing; statins
Mesh:
Substances:
Year: 2018 PMID: 29439058 DOI: 10.1136/practneurol-2017-001848
Source DB: PubMed Journal: Pract Neurol ISSN: 1474-7758